rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Cumulative evidence of an association was graded as strong for rs2294008 [odds ratio (OR) = 1.32, P = 5.1 × 10-33], rs2976392 (OR = 1.29, P = 1.8 × 10-8), rs9297976 (OR = 0.75, P = 1.4 × 10-7), rs2976391 (OR = 1.38, P = 6.1 × 10-5) and rs138377917 (OR = 0.53, P = 0.008) with gastric cancer, rs2294008 with bladder cancer (OR = 1.15, P = 8.0 × 10-19), gastritis (OR = 1.35, P = 1.2 × 10-5), duodenal ulcer (OR = 0.68, P = 2.4 × 10-57) and gastric ulcer (OR = 0.88, P = 1.7 × 10-7).
|
30407486 |
2019 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our meta-analysis supports that the PSCA gene variant rs2294008 polymorphism might contribute to individual susceptibility to bladder cancer.
|
31008939 |
2019 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
For the PSCA rs2294008 polymorphism, when stratified by type of cancer, the results were significant especially in gastric cancer and bladder cancer.
|
28881685 |
2017 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Based on the statistical evidence, we can draw a conclusion that the rs2294008 polymorphism of PSCA gene is likely to play a role in cancer carcinogenesis, especially in gastric cancer and bladder cancer.
|
26308216 |
2015 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, the results suggest that the PSCA rs2294008 (C>T) polymorphism is a risk factor for bladder cancer development.
|
25117309 |
2014 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our study showed that the rs2294008 polymorphism in the PSCA gene is associated with the risk of bladder cancer in a Korean population, providing evidence that it may contribute to bladder carcinogenesis regardless of ethnicity.
|
25374226 |
2014 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Overall, seven of the 14 variants were significantly associated with bladder cancer risk (p = 9.763 × 10(-3) for rs9642880 at 8q24.21, p = 3.004 × 10(-3) for rs2294008 at 8q24.3, p = 0.012 for rs798766 at 4p16.3, p = 0.034 for rs1495741 at 8p22, p = 2.306 × 10(-4) for GSTM1, p = 8.507 × 10(-8) for rs17674580 at 18q12.3, p = 7.179 × 10(-4) for rs10936599 at 3q26.2) and the odds ratios (ORs) ranged from 1.13 to 1.65.
|
24740636 |
2014 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The study suggests that anti-PSCA immunotherapy might be beneficial for bladder cancer patients with high tumor PSCA expression, which is statistically significantly associated with the presence of CT and TT genotypes of a common genetic variant, rs2294008.
|
23266392 |
2013 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
In conclusion, a joint effect of two PSCA SNPs, rs2294008 and rs2978974, suggests that both variants may be important for bladder cancer susceptibility, possibly through different mechanisms that influence the control of mRNA expression and interaction with regulatory factors.
|
22416122 |
2012 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results indicated that the rs2294008 pol</span>ymorphism of PSCA gene may play a role in bladder cancer carcinogenesis and it could be served as a biomarker for genetic susceptibility to bladder cancer in Chinese populations.
|
20083643 |
2010 |
rs2294008
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data identify rs2294008 as a new bladder cancer susceptibility locus.
|
19648920 |
2009 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
APEX1 rs3136817, MUTYH rs3219493, three SNPs (rs3213356, rs25487 and rs1799782) in XRCC1, and three SNPs (rs1799794, rs861531 and rs861530) in XRCC3 showed significant associations with the risk of bladder cancer.
|
27153553 |
2016 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The analysis suggests that the XRCC1 Arg399Gln polymorphism might be a moderate risk factor for bladder cancer, especially in non-Asian population.
|
24176953 |
2014 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We identified no association between the XRCC1 Arg399Gln polymorphism and bladder cancer risk.
|
25501209 |
2014 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The meta-analysis results suggest that XRCC1 Arg194Trp and Arg399Gln polymorphisms may be associated with elevated bladder cancer risk.
|
23496911 |
2013 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
This meta-analysis suggests that the XRCC1 R399Q polymorphism may play a protective role against bladder cancer among smokers.
|
24039945 |
2013 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We conducted a meta-analysis to ascertain the association of XRCC1 Arg194Trp, Arg280His and Arg399Gln polymorphisms with bladder cancer risk in Asian population.
|
23704969 |
2013 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
The overall data failed to indicate significant associations between XRCC1 A</span>rg399Gln polymorphism and bladder cancer risk (Gln/Gln versus Arg/Arg: odds ratio (OR) = 0.97; 95% CI = 0.85-1.10; dominant model: OR = 1.02; 95% CI = 0.94-1.09; recessive model: OR = 0.95; 95% CI = 0.84-1.07).
|
23479765 |
2013 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Significant increased risk of bladder cancer was observed for Arg194Trp polymorphism (allele comparison OR = 1.20, 95 % CI: 1.06-1.36, P heterogeneity = 0.11; dominant model OR = 1.20, 95 % CI: 1.02-1.41, P heterogeneity = 0.37) and Arg280His polymorphism (heterozygote comparison OR = 1.87, 95 % CI: 1.21-2.90, P heterogeneity = 0.01; dominant model OR = 1.75, 95 % CI: 1.05-2.90, P heterogeneity = 0.01); however, Arg399Gln was not associated with susceptibility to bladder cancer.
|
23636799 |
2013 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
We examined the associations between bladder cancer and 7 polymorphisms from 5 genes involved in the maintenance of genetic stability (MMR: MLH1-93G>A; BER: XRCC1--77T>C and Arg399Gln; NER:XPC Lys939Gln and PAT +/-; DSBR:ATM G5557A and XRCC7 G6721T) in 302 incident bladder cancer cases and 311 hospital controls.
|
22927776 |
2012 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
No association was found between the polymorphisms in XRCC1 (Arg(194)Trp, Arg(280)His, Arg(399)Gln) and bladder cancer susceptibility.
|
18336890 |
2008 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
It indicated that XRCC1 R399Q and R194W might not be risk factors to bladder cancer, but the 399QQ genotype decreased susceptibility of bladder cancer under recessive model and homozygote contrast among ever-smokers.
|
18765423 |
2008 |
rs25487
|
|
Bladder Neoplasm
|
|
0.100 |
GeneticVariation
|
BEFREE |
Our data are consistent with a potential role of the XRCC1 Arg399Gln polymorphism in bladder cancer susceptibility and further suggest that there may be DNA lesions important in bladder carcinogenesis, repaired by the base excision repair mechanism, that are not directly associated with tobacco smoking.
|
15298955 |
2004 |
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Quantitative assessment of the association between MHTFR C677T (rs1801133, Ala222Val) polymorphism and susceptibility to bladder cancer.
|
23773402 |
2013 |
rs1217691063
|
|
Bladder Neoplasm
|
|
0.090 |
GeneticVariation
|
BEFREE |
Results from the current update analysis suggested that the C677T and A1298C polymorphisms in the MTHFR gene were associated with BC risk and disease progression.
|
23578207 |
2013 |